[1]
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017; 17: 20-37.
[2]
Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008; 26(1): 57-64.
[3]
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14(5): 1310-6.
[4]
Gu FX, Karnik R, Wang AZ, et al. Targeted nanoparticles for cancer therapy. Nano Today 2007; 2(3): 14-21.
[5]
Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006; 5(8): 1909-17.
[6]
Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60(15): 1615-26.
[7]
Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
[8]
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
[10]
Babu A, Templeton AK, Munshi A, Ramesh R. Nanoparticle based drug delivery for therapy of lung cancer: progress and challenges. J Nanomat 2013; 2013: 1-11.
[11]
Ni XL, Chen LX, Zhang H, et al. 2017
In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer. Drug Deliv 2017; 24(1): 1501-12.
[12]
Lee WH, Loo CY, Young PM, et al. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv 2014; 11: 1183-201.
[13]
Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62(20): 5749-54.
[14]
Gupta M, Goswami K, Marwaha RK, Dureja H. Safety and antitumor activity of gefitinib: an overview. Int J Pharm Sci Res 2014; 5(11): 4129-40.
[15]
Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10(4): 1212-8.
[16]
Tikoo K, Kaur J. p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles. Biochimica et Biophysica Acta 2013; 1833: 1028-40.
[17]
Johan C, Katarina E, Roger P, Katarina J. Rheological evaluation of Gelrite in situ gels for ophthalmic use. Eur J Pharm Sci 1998; 6: 113-9.
[18]
Kesarla R, Tonk T, Vora PA, Shah T, Parmar S. Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel. Drug Deliv 2016; 23(7): 2363-70.
[19]
Sworn G, Sanderson GR, Gibson W. Gellan gum fluid gels. Food Hydrocolloids 1995; 9(4): 265-71.
[20]
Anwunobi AP, Emeje MO. Recent Applications of natural polymers in nanodrug delivery. J Nanomed Nanotechnol 2011; S4(02): 1-6.
[21]
Kurlyandskaya GV, Litvinova LS, Safronov AP, et al. Water based suspensions of iron oxide nanoparticles with electrostatic or steric stabilization by chitosan: fabrication, characterization and biocompatibility. Sensors 2017; 17: 2605.
[22]
Kuo CH, Liu YC, Chang CJ, Chen JH, Chang C, Shieh CJ. Optimum conditions for lipase immobilization on chitosan-coated Fe3O4 nanoparticles. Carbohydrate Polymers 2012; 87(4): 2538-45.
[23]
Yuan Q. Hein S, Misra RD. New generation of chitosan-encapsulated ZnO quantum dots loaded with drug: synthesis, characterization and in vitro drug delivery response. Acta Biomater 2010; 6(7): 2732-9.
[24]
Kouchak M, Avadi M, Abbaspour M, Jahangiri A, Boldaji SK. Effect of different molecular weights of chitosan on preparation and characterization of insulin loaded nanoparticles by ion gelation method. Int J Drug Dev Res 2012; 4(2): 271-7.
[25]
Gupta M, Marwaha RK, Dureja H. Development and characterization of gefitinib loaded polymeric nanoparticles by ionic gelation method. Pharmaceut Nanotechnol 2017; 5: 301-9.
[26]
Nagarajan E, Shanmugasundaram P. Ravichan diran V, Vijayalakshmi A, Senthilnathan B, Masilaman K. Development and evaluation of chitosan based polymeric nanoparticles of an antiulcer drug lansoprazole. J Appl Pharm Sci 2015; 5(04): 20-5.
[27]
Seifirad S, Karami H, Shahsavari S, Mirabbasi F, Dorkoosh FA. Design and characterization of mesalamine loaded nanoparticles for controlled delivery system. Nanomed Res J 2016; 1(2): 97-106.
[28]
Monograph on Gefitinib. In: Indian Pharmacopoeia. 6th ed. The Indian Pharmacopoeia Commission, Ghaziabad, Vol II 2010; p. 1405.
[29]
Calvo P, Remunan Lopez C, Vila Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997; 14: 1431-6.
[30]
Reddy HL, Murthy RSR. Etoposide loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release and stability evaluation. AAPS PharmSciTech 2005; 6(2): E158-66.
[31]
Correia Pinto JF, Csaba N, Schiller JT, Alonso MJ. Chitosan-poly (I:C)-Padre based nano- particles as delivery vehicles for synthetic peptide vaccines. Vaccines 2015; 3: 730-50.
[32]
Nallamuthu I, Devi A, Khanum F. Chlorogenic acid loaded chitosan nanoparticles with sustained release property, retained antioxidant activity and enhanced bioavailability. Asian J Pharm Sci 2015; 10(3): 203-11.
[35]
Mohammad M, Graeme G, Kenneth B. Effects of chemical conjugation of L-leucine to chitosan on dispersibility and controlled release of drug from a nanoparticulate dry powder inhaler formulation. Mol Pharm 2016; 13(5): 1455-66.
[36]
Grossman JH, McNeil SE. Nanoparticles in cancer medicine. Physics Today 2012; 3: 730-50.
[37]
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15(1): 25-35.
[38]
Srinivas NSK, Verma R, Kulyadi GP, Kumar L. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. Int J Nanomed 2017; 12: 15-28.
55
1